P21

This paper reports the design and initial in vivo characterization of the 11-mer synthetic peptide "Peptide 6," derived from a biologically active region of ciliary neurotrophic factor (CNTF). In adult C57BL/6 mice, peripherally administered Peptide 6 induced proliferation of neural progenitor cells and increased survival and maturation of newly-born neurons in the dentate gyrus, as quantified by BrdU incorporation and double-labeling for neuronal markers. The peptide also increased MAP2 and synaptophysin immunoreactivity in the dentate gyrus, consistent with enhanced dendritic and synaptic markers. A 30-day subcutaneous slow-release implant produced improved reference memory in the Morris water maze. The authors reported a plasma half-life of approximately 6 hours and described the peptide as blood-brain-barrier permeable, with a proposed mechanism of competitive inhibition of leukemia inhibitory factor (LIF) signaling. This is the foundational publication on the Peptide 6 / P21 lineage and was conducted by the originating research group at the New York State Institute for Basic Research in Developmental Disabilities.

Researchers wanted a small synthetic peptide that could copy part of what a natural growth factor for neurons (CNTF) does, but be small enough to cross from the bloodstream into the brain. They designed an 11-amino-acid peptide they called "Peptide 6" based on a piece of CNTF. When normal adult mice received the peptide under the skin for thirty days using a slow-release implant, the researchers observed more new neurons being born and surviving in a memory-related part of the brain called the dentate gyrus. The mice also performed better on a standard rodent memory test (the Morris water maze). The peptide stayed in the blood for about six hours and appeared to act by blocking a signal called LIF that normally slows neurogenesis. This is the founding study that defined the Peptide 6 / P21 family — it was carried out by the same lab that originally designed the molecule.

This study evaluated the tetrapeptide derivative P021 (Ac-DGGL) — a smaller analogue from the same Peptide 6 / P21 lineage — in the 3xTg-AD mouse model of Alzheimer's-type pathology. The authors reported that chronic oral administration of P021 in mice rescued deficits in dendritic and synaptic markers, supported hippocampal neurogenesis, and was associated with improved performance on cognitive tasks compared with vehicle-treated transgenic controls. The authors interpreted the findings as consistent with the proposed mechanism of LIF inhibition and increased BDNF expression described in the original Chohan et al. (2011) work. As with the foundational paper, this study originates from the Iqbal research lineage at the New York State Institute for Basic Research in Developmental Disabilities, and the same group has produced most of the follow-up rodent literature on this peptide family.

Researchers tested a smaller, more drug-like version of the original Peptide 6 — called P021 — in a mouse model that develops brain changes similar to Alzheimer's disease. The mice received the peptide by mouth over time. Compared with untreated mice from the same Alzheimer-model strain, the treated mice showed better-preserved connections between brain cells, more new neurons forming in the hippocampus, and better performance on memory tasks. The authors interpreted this as further evidence for the same mechanism the lab described in 2011 — blocking the LIF signal and raising BDNF. The work was done by the same research lineage that introduced the peptide, so independent replication by unrelated laboratories remains the key gap in the evidence base.